Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer.

Florio R, Veschi S, di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, Cataldi A, Amoroso R, Cama A, De Lellis L.

Cancers (Basel). 2019 Dec 17;11(12). pii: E2042. doi: 10.3390/cancers11122042.

2.

Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.

Ramassone A, D'Argenio A, Veronese A, Basti A, Soliman SHA, Volinia S, Bassi C, Pagotto S, Ferracin M, Lupini L, Saccenti E, Balatti V, Pepe F, Rassenti LZ, Innocenti I, Autore F, Marzetti L, Mariani-Costantini R, Kipps TJ, Negrini M, Laurenti L, Visone R.

J Hematol Oncol. 2019 Nov 19;12(1):114. doi: 10.1186/s13045-019-0802-x.

3.

DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells.

Visone R, Bacalini MG, Di Franco S, Ferracin M, Colorito ML, Pagotto S, Laprovitera N, Licastro D, Di Marco M, Scavo E, Bassi C, Saccenti E, Nicotra A, Grzes M, Garagnani P, De Laurenzi V, Valeri N, Mariani-Costantini R, Negrini M, Stassi G, Veronese A.

Epigenomics. 2019 May 1;11(6):587-604. doi: 10.2217/epi-2018-0153. Epub 2019 May 8.

4.

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.

Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Cancers (Basel). 2019 Apr 23;11(4). pii: E575. doi: 10.3390/cancers11040575.

5.

MicroRNAs in Autoimmunity and Hematological Malignancies.

Di Marco M, Ramassone A, Pagotto S, Anastasiadou E, Veronese A, Visone R.

Int J Mol Sci. 2018 Oct 12;19(10). pii: E3139. doi: 10.3390/ijms19103139. Review.

6.

Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation.

Pagotto S, Veronese A, Soranno A, Lanuti P, Di Marco M, Russo MV, Ramassone A, Marchisio M, Simeone P, Guanciali-Franchi PE, Palka G, Costantini RM, Croce CM, Visone R.

Oncotarget. 2018 Feb 7;9(16):13036-13047. doi: 10.18632/oncotarget.24437. eCollection 2018 Feb 27.

7.

Epigenetics and MicroRNAs in Cancer.

Ramassone A, Pagotto S, Veronese A, Visone R.

Int J Mol Sci. 2018 Feb 3;19(2). pii: E459. doi: 10.3390/ijms19020459. Review.

8.

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.

Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R.

Oncotarget. 2016 Aug 23;7(34):55395-55408. doi: 10.18632/oncotarget.10577.

9.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.

Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, Spizzo R, Zagatti B, Lanuti P, Fornari F, Ghasemi R, Mariani-Costantini R, Bolondi L, Gramantieri L, Calin GA, Sabbioni S, Visone R, Veronese A, Negrini M.

Oncotarget. 2016 May 24;7(21):31361-71. doi: 10.18632/oncotarget.8913.

10.

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.

Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, CorrĂ  F, Musa G, Callegari E, Lupini L, Volpato S, Querzoli P, Negrini M.

Mol Cancer. 2013 Oct 28;12(1):130. doi: 10.1186/1476-4598-12-130.

Supplemental Content

Loading ...
Support Center